Chemical Information Appearance Solid Molecular Weight 312.35 (free base) Formula C 10 H 12 D 5 N 3 O 6 S.xNH 3 Color White to off-white SMILES O=C(CNC([C@@H](NC(C([2H])(C([2H])([C@](N)(C(O)=O)[2H])[2H])[2H])=O)CS)=O)O.N.[x] Synonyms GSH-d5 ammonium
Screening of DNMT3A inhibitors from phytochemicals using molecular docking and molecular dynamics simulation for their anti-cancer potential
Figure 3 3.2 Integrated immune metabolic regulation of ferroptosis Ferroptosis involves aberrant iron metabolism, resulting in lipid peroxidation and the degradation of cellular membranes
Amylin and calcitonin receptor signalling mechanisms
Disclosures: Joanne Hsieh: Gordian Biotechnology: Employee, Vinay Kartha: Nothing to Disclose, Hikaru Miyazaki: Nothing to Disclose, Christopher Carrico: Nothing to Disclose, Linda Chio: Gordian Biotechnology: Employee, Gordian Biotechnology: Stock privately held company, Daniel Fuentes: Nothing to Disclose, Dimitry Popov: Nothing to Disclose, Ian Driver: Nothing to Disclose, Chris Towne: Nothing to Disclose, Francisco LePort: Nothing to Disclose, Martin Borch Jensen: Nothing to Disclose 2067 PHARMACOKINETICS, SAFETY AND EFFICACY OF THE NOVEL NON-BILE ACID FXR AGONIST FXR314 IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: RESULTS FROM A PHASE 2 STUDY Eric Lawitz 1 Kathryn Jean Lucas 2 Kris Kowdley 3 Naim Alkhouri 4 Stephen Harrison 5 Fabrice Piu 6 , 1 Texas Liver Institute, 2 Diabetes & Endocrinology Consultants, PC, 3 Liver Institute Northwest, 4 Arizona Liver Health, 5 University of Oxford, 6 Organovo, Inc Background Farnesoid X receptor (FXR) agonism has demonstrated clinical utility for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) but clinical development has been hampered by limited efficacy and adverse events (pruritus, dyslipidemia)
